Valuation: Polaris Group

Market Cap 8.88B 279M 242M 229M 208M 389M 26.8B 392M 2.73B 1.06B 13.59B 1.05B 1.03B 43.33B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 9.39B 296M 256M 242M 220M 412M 28.36B 415M 2.89B 1.12B 14.39B 1.11B 1.09B 45.85B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day+0.20%
1 week-3.22%
Current month-7.29%
1 month-9.41%
3 months-24.85%
6 months-54.29%
Current year-68.10%
1 week 9.88
Extreme 9.88
10.15
1 month 9.88
Extreme 9.88
13
Current year 9.88
Extreme 9.88
35.95
1 year 9.88
Extreme 9.88
38.45
3 years 9.88
Extreme 9.88
87.7
5 years 9.88
Extreme 9.88
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-3.22%-73.37%-88.44% 278M
+0.22%+0.07%-1.90%+8.24% 45.81B
-0.32%+4.61%+43.90%+26.98% 44.39B
-4.36%-5.66%+338.30%+516.88% 43.91B
+0.46%-0.83%+6.38%+73.76% 39.4B
-0.17%-3.22%+10.29%+38.69% 31.26B
-0.65%+5.14%+25.61%+120.17% 17.32B
+3.30%-5.03% - - 15.75B
+1.66%+5.30%+19.25%+34.93% 14.73B
+0.86%+9.05%+0.47%-33.54% 13.31B
Average +0.12%+0.07%+40.99%+77.52% 26.61B
Weighted average by Cap. -0.40%-0.28%+71.90%+121.85%

Financials

2024 2025
Net sales 107M 3.37M 2.92M 2.76M 2.5M 4.69M 323M 4.72M 32.93M 12.73M 164M 12.65M 12.37M 522M 40.6M 1.28M 1.11M 1.05M 950K 1.78M 123M 1.79M 12.5M 4.83M 62.18M 4.8M 4.69M 198M
Net income -2.5B -78.77M -68.26M -64.52M -58.57M -110M -7.56B -110M -770M -298M -3.83B -296M -289M -12.22B -3.93B -124M -107M -101M -91.91M -172M -11.86B -173M -1.21B -467M -6.01B -464M -454M -19.17B
Net Debt 9.19M 289K 251K 237K 215K 403K 27.76M 406K 2.83M 1.09M 14.08M 1.09M 1.06M 44.87M 517M 16.27M 14.1M 13.33M 12.1M 22.67M 1.56B 22.81M 159M 61.47M 792M 61.12M 59.76M 2.52B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
16/09/26 NT$9.920 +0.20% 1,037,484
15/09/26 NT$9.900 0.00% 1,026,794
14/09/26 NT$9.900 -0.70% 1,843,391
11/09/26 NT$9.970 -2.25% 2,230,580
10/09/26 NT$10.20 -0.49% 697,251
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!